🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So proud of Dr. Brinda Gupta. Already a pro at fielding questions! Georgetown Lombardi ASCO Hem-Onc Fellows Network Georgetown Hematology/Oncology Fellowship Stephen V Liu, MD #ASCO23 #NRG1 Caris Life Sciences

"Distinct Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) GI...)." Research by Jingyuan Wang, Joanne Xiu, Benjamin Weinberg, MD, FACP , John Marshall, Emil Lou, MD, PhD, FACP, Davendra Sohal, Michael J Hall, Heinz-Josef Lenz and others.

Proud to be part of exciting work as part of the Caris Life Sciences POA. Investigators from multiple institutions work on projects together in real time. This is exactly what we need to care for patients w brain ca 👉🏻 more to come on these posters later #asco23 #btsm Levine Cancer

I've thought about this @nejm paper for years, and just again at #ASCO23 Yes, it's a single-institution analysis but I think Memorial Sloan Kettering Cancer Center showed provocatively why we shouldn't rush to embrace TMB > 10 as a histology-agnostic marker of IO benefit pubmed.ncbi.nlm.nih.gov/33761214/

#ASCO23 FIRE-4 study: Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC 💥Liquid biopsy detected RAS mutation in 13% of patients deemed RASwt based on tissue analyses❗️ 📌These patients had

“Clinical genomic implications of transcriptional subtypes in pancreatic cancer.” Research by Dr. Harshabad Singh, Joanne Xiu, Benjamin Weinberg, MD, FACP, Mike Pishvaian, Rachna Shroff, MD, MS, FASCO, Emil Lou, MD, PhD, FACP, John Marshall, Heinz- Joseph Lenz and others. Dana-Farber Georgetown Lombardi Caris Life Sciences #ASCO23

#ASCO23 The importance of circadian rhythm A very interesting study.. 💥According to this study, evening tamoxifen intake is associated with an improved DFS in high-risk HR+/HER2- breast cancer patients The work of Dr. Sylvie Giacchetti and colleagues👇 OncoAlert

Drug development is cool ! Check out this video --> The most exciting part of our Cancer Discovery paper is the FGFR1 vs FGFR2 video in the supplemental section AACR In this schematic movie, apo FGFR1 (left panel) demonstrates rapid P-loop dynamics, while apo FGFR2 (right panel)

Now online in npj Journals: "PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system." From the team of Dr. Andreas Seeber @imed_tweets and Caris Life Sciences GI Onc Precision Oncology Alliance collaboration.

A nature paper published today reports 👉🏼Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Lung cancer targeted therapies commonly used in the clinic can induce cytidine deaminase APOBEC3A (A3A), leading to sustained mutagenesis in drug-tolerant cancer cells

A mind-blowing paper has come out today in nature In 2016, JC Venter Institute scientists trimmed a bacterial genome to its barest minimum required for life to synthesize what they called a "minimal genome" (science.org/doi/10.1126/sc…). Today, a group of scientists from

Sunday thoughts.

If you treat colorectal cancer #CRC or Endometrial Cancer #EC, you may find our paper interesting. Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations - PubMed #colorectalcancerawarenessmonth pubmed.ncbi.nlm.nih.gov/38350001/

Results from the SWOG S1314 trial validate earlier findings in ATM, RB1, ERCC2, or FANCC predict CR to NAC in muscle-invasive bladder cancer.. not perfect but predictive .. with NPV 86% .. better at predicting presence of disease > absence sciencedirect.com/science/articl… European Urology

This week, we highlighted research by Harshabad Singh,Joanne Xiu, Raja Narayan, MD MPH, Benjamin Weinberg, MD, FACP Mike Pishvaian, Rachna Shroff, MD, MS, FASCO, Jonathan A. Nowak, Andrew Aguirre and others published in Clinical Cancer Research. Learn more: bit.ly/40KQYNk.

If you are someone who Caris to offer the optimal treatment for your patients- note this excellent paper by Joshua Reuss Stephen V Liu, MD and our Caris POA team - expanded biomarker testing is a MUST for pts w no or limited h/o smoking diagnosed w SqNSCLC! Caris Life Sciences Joanne Xiu

The Mystery of Rising GI Cancers in Young Adults; Colorectal, liver, and gastric cancers are increasingly affecting younger adults, and the numbers are alarming: Why is this happening? And what can we do about it? Follow along as we investigate. The case isn’t closed yet #GI25

“Investigating the clinical and molecular characteristics of​ class II and III BRAF mutations and their response to anti-EGFRtherapy in MSS CRC: A comprehensive analysis.” Ibrahim Halil SAHIN, MD, Joanne Xiu, Moh'd Khushman, Emily Palumbo, Benjamin Weinberg, MD, FACP, Sanjay Goel, Mehmet Akce,

If you treat CRC patient and you came across a patient with MSI-H and NTRK fusion, you might find this case and literature review helpful. ascopubs.org/doi/10.1200/PO…

Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 Nature Medicine